Next Article in Journal
A Systematic Review of Advances in Plant-Based Phospholipid Liposomes in Breast Cancer Therapy: Characterization, Innovations, Clinical Applications, and Future Directions
Previous Article in Journal
Structure–Function Insights into Quinuclidine-3-One BisQACs: Synthesis, Modulation of Bacterial Resistance, Structure–Activity Relationship, and Biological Profiling
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 18
Issue 9
10.3390/ph18091287
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Pharmaceuticals 2023, 16(12), 1711.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711

by
Aeshah A. Awaji
1,
Moustafa A. Rizk
2,
Raiedhah A. Alsaiari
2,
Norah F. Alqahtani
3,
Fatima A. Al-Qadri
2,
Ali S. Alkorbi
2,
Hani S. Hafez
4,* and
Reda F. M. Elshaarawy
5,6,*
1
Department of Biology, Faculty of Science, University College in Taymaa, University of Tabuk, Tabuk 71491, Saudi Arabia
2
Department of Chemistry, Faculty of Science and Arts at Sharurah, Najran University, Sharurah 68342, Saudi Arabia
3
Department of Chemistry, College of Science, University of Jeddah, Jeddah 21589, Saudi Arabia
4
Zoology Department, Faculty of Science, Suez University, Suez 43533, Egypt
5
Department of Chemistry, Faculty of Science, Suez University, Suez 43533, Egypt
6
Institut für Anorganische Chemie und Strukturchemie, Heinrich-Heine Universität Düsseldorf, 40204 Düsseldorf, Germany
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(9), 1287; https://doi.org/10.3390/ph18091287
Submission received: 26 June 2025 / Accepted: 4 July 2025 / Published: 28 August 2025
Browse Figure
Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 4 as published. This was an error related to image production during the authors’ preparation of the figures. The corrected Figure 4 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Awaji, A.A.; Rizk, M.A.; Alsaiari, R.A.; Alqahtani, N.F.; Al-Qadri, F.A.; Alkorbi, A.S.; Hafez, H.S.; Elshaarawy, R.F.M. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 18 01287 g004
Figure 4. (A–F) Quantitative measure for 100 cells on a scale from 0 to 400.
Figure 4. (A–F) Quantitative measure for 100 cells on a scale from 0 to 400.
Pharmaceuticals 18 01287 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Awaji, A.A.; Rizk, M.A.; Alsaiari, R.A.; Alqahtani, N.F.; Al-Qadri, F.A.; Alkorbi, A.S.; Hafez, H.S.; Elshaarawy, R.F.M. Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711. Pharmaceuticals 2025, 18, 1287. https://doi.org/10.3390/ph18091287

AMA Style

Awaji AA, Rizk MA, Alsaiari RA, Alqahtani NF, Al-Qadri FA, Alkorbi AS, Hafez HS, Elshaarawy RFM. Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711. Pharmaceuticals. 2025; 18(9):1287. https://doi.org/10.3390/ph18091287

Chicago/Turabian Style

Awaji, Aeshah A., Moustafa A. Rizk, Raiedhah A. Alsaiari, Norah F. Alqahtani, Fatima A. Al-Qadri, Ali S. Alkorbi, Hani S. Hafez, and Reda F. M. Elshaarawy. 2025. "Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711" Pharmaceuticals 18, no. 9: 1287. https://doi.org/10.3390/ph18091287

APA Style

Awaji, A. A., Rizk, M. A., Alsaiari, R. A., Alqahtani, N. F., Al-Qadri, F. A., Alkorbi, A. S., Hafez, H. S., & Elshaarawy, R. F. M. (2025). Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711. Pharmaceuticals, 18(9), 1287. https://doi.org/10.3390/ph18091287

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop